The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2026 | Efficacy and safety of single-fraction SABR for primary NSCLC and lung oligometastases
Neil Wallace, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses efficacy and safety results from a pooled analysis of 1691 patients examining single-fraction stereotactic ablative body radiotherapy (SABR) for primary non-small cell lung cancer (NSCLC) and lung oligometastases. Low toxicity was found across both sites with a 3% rate of grade 3 or above adverse events, however primary NSCLC reported a higher rate of 15% grade 2 and above adverse events compared with 7% for oligometastases. Both showed excellent local control of over 90% after two years. There was a difference seen in the patterns of failure, with the most common first failure event of death in primary NSCLC and distant relapse in the oligometastatic setting. Overall survival was slightly longer in oligometastases but in both settings, the treatment is reported to be effective and safe. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
